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INTRODUCTION
Carcinogenicity is a long-standing issue that is of great concern to the scientific community worldwide, and assessment of the carcinogenic potential of compounds typically begins with genotoxicity testing. Most genotoxicity data, however, are derived from in vitro assays, and in vivo studies are often done using acute treatment modes that do not employ repeat dosing, as is often the case for human exposures. Even so, in vivo studies are considered of value because they incorporate many factors not present in vitro that may influence the genotoxic activity of a chemical, such as toxicant deposition, metabolism, and elimination. Therefore, in addition to their use in follow-up observations of positive results in vitro, in vivo assays are indispensable parts of the standard battery of genotoxicity tests. The recently adopted ICH S2 (R1) guidelines (ICH, 2011) have placed higher demands on in vivo studies than ever before, recommending options that include using either one or two in vivo tests for genotoxicity. In addition, the guidelines recommend integrating the measurement of in vivo genotoxicity endpoints into a single general toxicology study where feasible. The combination of several assays may reduce animal use, which is consistent with the 3Rs principles for animal welfare, and save considerable time and cost in the safety evaluation of drug candidates. Moreover, integration facilitates the evaluation of a potential genotoxic response in the context of other genetic and/or general toxicology endpoints. For example, it enables comprehensive comparative analyses when determining genotoxicity, subchronic/chronic toxicity, metabolism, and pharmacokinetic information using the same animals (Krishna et al., 1998; Pfuhler et al., 2009; Rothfuss et al., 2011) .
Currently, the most commonly used in vivo assay is micronucleus evaluation in rodent bone marrow or peripheral blood, which detects aneugenic and/or clastogenic chromosomal damage. The mammalian erythrocyte micronucleus test is the primary regulatory assay for the assessment of chromosomal damage in vivo (OECD, 1997) . In addition to scoring micronuclei on slides using a microscope, the flow cytometry-based automated analysis method for the enumeration of micronuclei in peripheral blood reticulocytes has been validated over decades of use and was adopted by OECD in 2014 Torous et al., 2005; Dertinger et al., 2006; Kasamoto et al., 2014; OECD, 2014) .
Compared with reports on aneugenicity and clastogenicity, many fewer studies have been published on DNA damage detection (i.e., using the Comet assay). According to the recently adopted ICH S2 (R1) guidelines (ICH, 2011) , Option 2 suggests that following an assessment of gene mutation in bacteria and one in vivo genotoxicity assay (micronucleus test in bone marrow or blood), the Comet assay is suitable for use as a second in vivo assay for evaluating genotoxicity in another target tissue. However, a drawback to the use of the micronucleus and Comet assays is that detection of genotoxic potential does not benefit from repeated exposure because these endpoints are only sensitive to relatively short-term exposure to the genotoxic agent prior to the sampling time. Thus, the detection of the micronucleus and Comet endpoints must be conducted within a few hours or a couple of days after terminal administration.
In contrast to clastogenicity (or aneugenicity) and DNA damage, induced gene mutations can accumulate in vivo as a consequence of repeated exposure (Hitotsumachi et al., 1985; Aidoo et al., 1993) , and therefore, in vivo gene mutation assays may be particularly well suited for integration into repeated dose studies. Until recently, the most often mentioned existing in vivo gene mutation approaches include the lymphocyte Hprt assay (Aidoo et al., 1997) , the human glycophorin A assay (Langlois et al., 1986) , and the various transgene rodent models using bacterial genes as targets for mutation (e.g., lacI or lacZ gene) (Lambert et al., 2005) . However, these assays have significant limitations in their ability to serve regulatory purposes for evaluating gene mutation, such as relatively intensive labor requirements, costly transgene models, or restrictions on cross-species potential. Consequently, the development of a sensitive, relatively simple, and truly economic test for measuring gene mutation in vivo has been a major unmet goal of genotoxicity safety assessments.
In recent years, several new rodent-based in vivo assays have been developed and optimized for monitoring mutations at the X-chromosome Phosphatidylinositol glycan class A (Pig-a) locus. These in vivo Pig-a assays were first described for rats and mice in 2008 Phonethepswath et al., 2008; Miura et al., 2008a; 2008b) , and they attracted almost immediate interest, which resulted in intensive studies and global validation trials for performance characteristics (Dertinger et al., 2011b; Kimoto et al., 2013) . Previous observations have shown that the Pig-a assay has several attractive advantages in comparison to other in vivo genetic toxicology tests. One advantage is that the Pig-a gene, as an endogenous reporter, has a high degree of interspecies conservation of its structure, function, and location on the X-chromosome (Kawagoe et al., 1994) . Thus, the results of early studies in test animals can be applied to humans for clinical research. Furthermore, Pig-a mutant erythrocytes induced by some agents (e.g., Nethyl-N-nitrosourea) can accumulate in a nearly additive fashion with repeated dosing in rodents and persist for considerable periods of time in peripheral blood (Miura et al., 2009; Dobrovolsky et al., 2010) . These characteristics of Pig-a mutation could be important for detecting weak mutagens by repeated dosing protocols (e.g., 28-or 90-day). In addition, the use of peripheral blood allows the determination of Pig-a mutant frequencies before, during, and after the treatment schedule, making it possible to collect longitudinal data and hence benefit the integration of the Pig-a endpoint into established subchronic/chronic toxicity studies or other genotoxicity assays without compromising the measurement of other toxicology endpoints. Thus, gene mutation responses can be measured in relation to other endpoints in one set of test animals (Gollapudi et al., 2015) .
Although the results of intra-inter-laboratory trials indicate that, with adequate training of personnel, the erythrocyte-based Pig-a assay is highly reproducible and readily transferable (Dertinger et al., 2011b) , more research remains to be conducted, including analyses of additional test agents, especially weakly mutagenic or nongenotoxic agents (Gollapudi et al., 2015) . In this study, we have chosen two genotoxic compounds, procarbazine hydrochloride and ethyl carbamate that both are difficult to evaluate using in vitro assays, for further testing. We have evaluated the integration of the Pig-a mutation assay, along with other genotoxicity endpoints including the micronucleus and Comet assays, into standard general toxicology studies in Sprague-Dawley rats. Moreover, we have confirmed Environmental and Molecular Mutagenesis. DOI 10.1002/em previously observed performance characteristics of the Pig-a endpoint in the context of two commonly employed experimental designs (3-day and 28-day studies). In so doing, we have compared the sensitivity of various genotoxicity endpoints to different treatment protocols, and analyzed the strengths and limitations of the Pig-a assay relative to the micronucleus and Comet assays when used in integrated study designs. 
MATERIALS AND METHODS

Reagents
Animals and Treatments
All experimental procedures, including the study protocol and number of animals, were approved by the Institutional Animal Care and Use Committee of the National Center for Safety Evaluation of Drug (Beijing, China), and the study was conducted in compliance with Good Laboratory Practice regulations. Male Sprague-Dawley (SD) rats were purchased from Beijing Vital River Laboratory Animal Technology Co., Ltd (Beijing, China). Rodents were allowed to acclimate for~1 week before treatment, and their age at the start of administration was 6-7 weeks. Water and food were available ad libitum throughout the acclimation and experimental periods, except when fasted overnight prior to sacrifice. Experimental animals were housed in an environmentally controlled room with temperatures between 20 and 25 C, a relative humidity of 40-70%, at least 15 changes of fresh HEPA-filtered air every hour, and a 12-hr light/dark cycle. General daily clinical observations and weekly detailed observations were performed for each animal. Body weight and food consumption were monitored throughout the study period.
An overview of the animal groups is presented in Table I . PCZ and EC were prepared fresh in ultrapure water on each day of treatment and administered via oral gavage in a volume of 10 mL/kg body weight/day at 24 hr intervals. For the 3-day study, a total of 10 rats per group (5 rats for Group IA and 5 additional rats for Group IB) were treated with vehicle, 75 mg PCZ/kg/day, 150 mg PCZ/kg/day, 400 mg EC/kg/day, or 800 mg EC/kg/day on Days 1, 2, and 3. For the 28-day study, a total of 10 rats per group (5 rats for Group IIA and 5 additional rats for Group IIB) were treated with vehicle, 30 mg PCZ/kg/day, 60 mg PCZ/kg/day, 150 mg EC/kg/day, or 300 mg EC/kg/day on Days 1-28. The high-dose levels for PCZ and EC were based on preliminary dose range-finding experiments. In accord with the OECD Guideline for the Testing of Chemicals No. 407 (OECD, 2008) , the high dose was identified as the highest dose level that induced toxic effects but not death or severe suffering.
The study schemes for the 3-day and 28-day studies are summarized in Figure 1 . Briefly, 5 of 10 animals in each group (Group IA and IIA) were administered an extra treatment dose prior to sacrifice on Day 4 for the 3-day study and Day 29 for the 28-day study, respectively. These five animals were used for conducting the micronucleus and Comet assays, while five additional animals (Group IB and IIB) were used for peripheral blood sampling to conduct the Pig-a mutation assay throughout the duration of the study. Additionally, the treated animals in Group IIA and IIB in the 28-day study were evaluated for clinical pathology.
Blood and Tissue Collection
Blood collection for various assays/endpoints was conducted using the volumes and timepoints as summarized in Table II . For the Pig-a assay, peripheral blood was collected from Group IB animals on Days −1, 16, 30, and 45 for the 3-day study, and from Group IIB animals on Days −1, 15, 28, 43, and 57 for the 28-day study (Fig. 1 ). Blood was obtained by nicking a lateral tail vein with a surgical blade after the animals were warmed briefly under a heat lamp. Approximately 120 μL of free-flowing blood was collected directly into heparinized capillary tubes (Fisher Scientific, Waltham, MA; . Then, 80 μL of each blood sample was transferred to vials containing 100 μL kit-supplied heparin solution, where they remained at room temperature for <2 hr until leukodepletion, as described previously (Dertinger et al., 2011a) .
For the micronucleus and Comet assays, Group IA and IIA animals were given an extra treatment dose on Day 4 for the 3-day study and on Day 29 for the 28-day study, respectively ( Fig. 1) , and anesthetized~3 hr later by CO 2 asphyxiation. Upon euthanasia,~250 μL of blood was collected from each animal directly into sodium heparin-coated vials via the inferior vena cava and used for the micronucleated reticulocytes (MN-RET) and Comet assays. Following blood collection, the unilateral femur of each animal was preserved for later bone marrow cell harvest for the micronucleated polychromatic erythrocytes (MN-PCE) assay, while several tissues, including liver, kidney, and lung, were obtained for the Comet Five animals in each group were classified into Group IA (for the 3-day study) or Group IIA (for the 28-day study), which were used for the micronucleus and Comet assays, while five additional animals were classified into Group IB (for the 3-day study) or Group IIB (for the 28-day study), which were used for the Pig-a mutation assay throughout the duration of the study.
Environmental and Molecular Mutagenesis. DOI 10.1002/em assay. Note that the Comet analyses of these tissues were only performed for the 28-day study but not the 3-day study. Furthermore, an additional timepoint for the MN-RET and Comet assays was included in the 28-day study ( Fig. 1) , at which time~250 μL of free-flowing blood was obtained 3 hr after the daily dose on Day 4 by nicking a lateral tail vein as described above. For the MN-RET endpoint, 60-120 μL of each blood sample was transferred to vials containing 350 μL kit-supplied heparin solution, where they remained at room temperature for <2 hr prior to being fixed with ultracold methanol as described previously (Torous et al., 2003) . For the MN-PCE endpoint, bone marrow from each animal was flushed out of the unilateral femur with 1 mL fetal bovine serum and then further processed for detection of the endpoint as described below. For the Comet endpoint,~100 μL of each blood sample was diluted with sodium heparin, while a small section of each tissue (liver, kidney, and lung) was cut and placed into the 5-mL centrifuge tubes containing 3 mL prechilled mincing solution (i.e., 20 mM EDTA in HBSS, Ca + and Mg + -free solution, with 10% DMSO added just before use), and then immediately minced into very small pieces to release cells using small dissecting scissors, finally generating a single cell suspension. The diluted blood samples and single cell suspensions of each tissue were prepared for mixing with molten LMAgarose as described below. The remaining large sections of liver, kidney, and lung from Group IIA animals were placed in 10% neutral-buffered formalin for potential histopathology analysis (not performed). Table I . The details of the blood collection and measured parameters for clinical pathology are presented in Table II and Supporting  Information, Table I Environmental and Molecular Mutagenesis. DOI 10.1002/em
For clinical pathology observation in the 28-day study, Group IIA animals were sacrificed on Day 29, while Group IIB animals were sacrificed on Day 58. Animals were anesthetized by CO 2 asphyxiation and then dissected immediately. A large volume of blood was collected via the inferior vena cava upon euthanasia. A minimal volume of blood was collected for the micronucleus and Comet assays from Group IIA animals on Day 29, whereas the remaining volume of blood from these animals on Day 29 as well as whole blood collected from Group IIB animals on Day 58 was used for hematology and clinical chemistry examination ( Fig. 1 and Table II ). Five hundred microliters of blood was collected into vials that were spray-coated with potassium EDTA for hematology analysis; 1.8 mL of blood was collected into vials containing sodium citrate for measuring the blood clotting time; and~1.5 mL of blood was collected into vials without anticoagulant to prepare serum for clinical chemistry evaluation. At necropsy, liver, kidneys, lung, spleen, thymus, adrenals, testis, and epididymides were extracted and weighed. Note that a small section of liver, kidney, and lung was used for Comet analysis on Day 29 as described above. For potential histopathology analysis (not performed), testis and epididymides were preserved in Davidson's solution, whereas other tissue samples (including the remaining large section of liver, kidney, and lung from Group IIA animals) were stored in 10% neutral buffered formalin.
Pig-a Assay
Pig-a mutant frequencies were analyzed for blood samples collected on Days −1, 16, 30, and 45 for the 3-day study and on Days −1, 15, 28, 43, and 57 for the 28-day study (Fig. 1) . The processing and labeling of blood samples for Pig-a determinations were conducted as described in the in vivo MutaFlow ® kit manual (version 140403) and have been described previously (Dertinger et al., 2011a) . A FACSCalibur flow cytometer (BD Biosciences) providing 488 and 633 nm excitation and running CellQuest™ Pro v6.0 software was used for data acquisition and analysis. On each day of data acquisition, an Instrument Calibration Standard (ICS) was generated by creating a sample with~50% wild-type cells and 50% mutant-mimicking cells. The resulting ICS sample provided sufficient numbers of red blood cells exhibiting a full range of PE and SYTO 13 fluorescence intensities that were useful for optimizing the photomultiplier tube voltages and fluorescence compensation settings on a daily basis. The position of the mutant-mimicking cells also provided a rational approach for defining the vertical demarcation line to distinguish mutant from wild-type cells. The gating logic and stop modes followed the kit manual. The acquired pre-column and post-column data were used to calculate the frequency of reticulocytes (RET), CD59-negative reticulocytes (RET CD59− ), and CD59-negative erythrocytes (RBC CD59− ).
Peripheral Blood MN-RET Assay
The measurements of MN-RET frequency were conducted using blood samples collected on Day 4 for the 3-day study and on Days 4 and 29 for the 28-day study (Fig. 1) . Blood was processed, labeled, and analyzed in accordance with the in vivo MicroFlow ® kit manual (version 130712), as described in detail elsewhere (Torous et al., 2003) . Briefly, 180 μL of diluted blood sample was fixed in 2 mL ultracold methanol for at least 3 days at −75 to −85 C. Before flow cytometric analysis, the blood sample was washed to remove the fixative and then incubated in the dark with labeling solution II (consisting of RNase solution, anti-CD71 antibody, and platelet antibody) for 30 min at 4 C and for 30 min at room temperature, respectively. As described in the kit manual and previously (Torous et al., 2003) , malaria-infected erythrocytes served as biological standards and guided the instrument settings on each day of data acquisition. Approximately 20,000 CD71-positive RETs per blood sample were scored for the frequency of MN-RET using a FACSCalibur flow cytometer (BD Biosciences) running CellQuest™ Pro v6.0 software, while the percentage of reticulocytes (%RET) for each sample was examined as an indicator of bone marrow cytotoxicity.
Bone Marrow MN-PCE Assay
Determinations of the MN-PCE endpoint were performed using bone marrow samples collected on Day 4 for the 3-day study and on Day 29 for the 28-day study (Fig. 1) . Bone marrow was flushed out of the femur using a syringe with 1 mL fetal bovine serum and then transferred to a 15-mL centrifuge tube followed by centrifugation for 5 min. After the majority of the supernatant was aspirated, bone marrow cells were resuspended in a small volume of the remaining fetal bovine serum and then spread onto a clean glass slide (3 slides/animal). The slides were air-dried at room temperature, fixed in methanol for 15 min, and then air-dried before staining. The blindly coded slides were measured by two staining methods. One slide was stained with 3-5% Giemsa for 15-20 min and washed with water prior to scoring. The other two slides were stained with acridine orange for 1-3 min followed by 3 immersions in PBS for 1-3 min each, and then scored by fluorescence microscopy. A total of 200 erythrocytes per animal were evaluated for the relative proportion of polychromatic erythrocytes to erythrocytes (PCE/ERY ratio or %PCE) as an index of cytotoxicity to the hematopoietic system; a total of 1000 PCEs per animal were evaluated for the frequency of MN-PCE.
Alkaline Comet Assay
The Comet endpoint was examined using blood samples collected on Day 4 for the 3-day study and Days 4 and 29 for the 28-day study, as well as liver, kidney, and lung collected on Day 29 for the 28-day study (Fig. 1) . The approach used for sample preparation and processing was determined according to the TREVIGEN ® CometAssay ® reagent kit instructions with minor modifications. Briefly, diluted blood samples or cell suspensions of liver, kidney, and lung were combined with molten LMAgarose (at 37 C) at a ratio of 1:10 (v/v), and 50 μL of the mixture was immediately pipetted into each well in a kit-supplied CometSlide™ (2 wells per sample). The slides were placed flat and allowed to gel at 4 C in the dark for 30 min. After gelation, the slides were immersed in prechilled kit-supplied lysis solution with 10% DMSO and stored at 4 C overnight in the dark.
Upon completion of cell lysis, the slides were drained of excess buffer and then immersed in freshly prepared alkaline unwinding solution (200 mM NaOH and 1 mM EDTA, pH >13) for 20-30 min at room temperature in the dark. Following unwinding, the slides were electrophoresed in the same solution at 0.7 V/cm, 300 mA, and 2-8 C for 20 min. After electrophoresis, the slides were gently drained of excess buffer, neutralized twice in 0.4 M Tris-base, pH 7 for 5 min each and then dipped in anhydrous ethanol for 20 min. The slides were air-dried and stored at room temperature prior to analysis. Each circle of dried agarose in the slides was stained with kit-supplied diluted SYBR ® Green I solution at 4 C in the dark for 5 min. The slides were gently eliminated of excess SYBR solution and then allowed to dry completely at room temperature in the dark. The slides were examined under a fluorescence microscope at 80× total magnification using FITC filters. Images of the Comets were analyzed using Komet software (version 6.0; Andor Technology, Belfast, UK). For each sample, 100 cells (i.e., 50 cells per well) were scored for the percentage of DNA in the tail (%tail DNA), tail length, and Olive tail moment, and an additional 100 cells per sample were independently scored for clouds and diffused cells.
Hematology and Clinical Chemistry
The analyses of standard hematology and clinical chemistry were conducted using blood samples collected from Group IIA animals on Day 29 and for Group IIB animals on Day 58 for the 28-day study (Fig. 1) . The measured parameters are listed in Supporting Information, Table I .
Environmental and Molecular Mutagenesis. DOI 10.1002/em Hematology samples were determined using an ADVIA 120 Hematology System (Bayer HealthCare, Diagnostics Division, Tarrytown, NY), and clinical chemistry samples were evaluated using a Rapidchem™ 744 (Bayer HealthCare, Diagnostics Division, Tarrytown, NY). In addition, measurements of blood clotting time, including prothrombin time and activated partial thromboplastin time, were performed on a Sysmex CA-1500 System (Sysmex Corporation, Kobe, Japan).
Calculations and Statistical Analyses
Calculations used for evaluating data from the Pig-a assay (RET percentages as well as the mutant-phenotype cell frequencies derived from the pre-and post-column data) were conducted using formulas available online (https://litronlabs.com/Resources/Downloads) and have been described previously (Dertinger et al., 2011a) . The frequencies of RBC CD59− and RET CD59− are expressed as the number of mutant cells per one million total RBCs or RETs, respectively, while the incidence of RETs, MN-RET, PCEs, and MN-PCE is expressed as a frequency percentage. All statistical analyses were performed by using SPSS Statistics 19 (IBM, Armonk, NY).
For genotoxicity endpoints, Pig-a, MN-RET, and MN-PCE data were transformed prior to performing statistical analyses as described previously (Dertinger et al., 2012) . MN-RET and MN-PCE frequencies were arcsinetransformed following the extraction of square root, while RBC CD59− and RET CD59− frequencies were log (10)-transformed. Note that a 0.1 offset was added to each RET CD59− value before log transformation to prevent the occurrence of zero values. These transformed data were analyzed using one-way analysis of variance (ANOVA), followed by Dunnett's t-test to compare each treatment group to the vehicle control. Significance was established at the level of P < 0.05 using a one-sided test to identify increases relative to the vehicle control. The same analyses were performed for untransformed %RET, %PCE, and median %tail DNA data, but in these cases, the tests were two-sided.
For the hematology, clinical chemistry, body weight, food consumption, and organ weight data, Levene's test was used to analyze homogeneity of variance. In the case of variance homogeneity (P > 0.05), homogeneous data were tested by one-way ANOVA followed by a twosided Dunnett's t-test for pairwise comparisons with the concurrent vehicle control. In the case of heterogeneity of variance (P < 0.05), heterogeneous data were analyzed using the Kruskal-Wallis test followed by a two-sided Dunnett's t-test for pairwise comparisons with the concurrent vehicle control. Significance was established at the level of P < 0.05 using a two-sided test to identify differences relative to the vehicle control.
RESULTS
3-Day Study
Pig-a Assay
As shown in Figure 2A , %RET measured during Pig-a analyses was not reduced by treatments with PCZ for three consecutive days. Rather, statistically significant increases in %RET values were observed on Day 16 for the low-dose group and on Days 16, 30, and 45 for the high-dose group. These effects were likely due to a compensation for the significant regression of erythropoiesis during the frequencies versus time. All error bars represent the standard error of the mean (SEM). Statistically significantly differences (*) from the same-day vehicle control values were established at P < 0.05 using a one-sided Dunnett's t-test (except %RET for the two-tailed test).
administration period, which is consistent with the Day 4 %RET measurements associated with blood micronucleus analyses revealing marked dose-dependent reductions in the PCZ-treated groups (Fig. 4A) . RET CD59− frequencies increased rapidly following exposure to PCZ for three consecutive days (Fig. 2B) . The greatest response was observed on Day 16, when the high-dose group exhibited a mean RET . Elevated RET CD59− values declined with additional time, yet they remained higher than the concurrent vehicle control until at least the last time point studied. PCZ-induced RBC CD59− frequencies increased more slowly than RET CD59− , and the maximal mean RBC CD59− value of 105.9 AE 31.9 × 10 −6 was expressed in the high-dose group on Day 30 (Fig. 2C) .
In contrast, modest increases in %RETs without statistical significance occurred on Day 16 at each dose of the EC-treated groups, which did not show evidence of appreciable bone marrow toxicity (Fig. 3A) . However, this endpoint exhibited a considerable dose-related decrease when measured in conjunction with micronuclei, 24 hr after the last administration on Day 4 (Fig. 4B) .
Significant dose-dependent increases in mean RET CD59− frequencies were observed in EC-treated animals (Fig. 3B) .
The maximal value of 31.9 AE 5.9 × 10 −6 for the high-dose group occurred on Day 16. Only the high-dose EC group retained statistical significance in the RET CD59− frequency value beyond Day 16. The two EC-treated groups showed relatively slower and more stable increases in mean RBC CD59− frequencies, with the greatest value of 14.0 AE 2.5 × 10 −6 occurring in the high-dose EC group at the terminal time point (Day 45; Fig 3C) .
Peripheral Blood MN-RETAssay
As shown in Fig. 4A , statistically significant, dosedependent increases in MN-RET frequencies were observed for the PCZ-treated groups in the blood micronucleus analyses, where the maximal value of 3.83 AE 0.64% (an~25.5-fold increase over the vehicle control) was detected in the 150 mg/kg/day group on Day 4. EC also significantly increased %MN-RET in a dose-related manner, with the highest mean value of 1.99 AE 0.25% (an~13.2-fold increase over the vehicle control) in the top-dose group 24 hr after the last treatment (Fig. 4B) . As mentioned above, these increases in %MN-RET values for the PCZ and EC groups were accompanied by significant reductions in %RET on Day 4. Statistically significantly differences (*) from the same-day vehicle control values were established at P < 0.05 using a one-sided Dunnett's t-test (except %RET for the two-tailed test).
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Bone Marrow MN-PCE Assay
In agreement with the %MN-RET endpoint, PCZ and EC treatment also produced similar responses in the Day 4 bone marrow micronucleus analyses, where %MN-PCE markedly increased at each dose level (Fig. 5) . For the PCZ treatment groups, the greatest mean MN-PCE frequencies were observed at the high-dose level: 3.50 AE 0.65% versus 0.20 AE 0.03% for the control, an~17.5-fold increase relative to the control (Fig. 5A) . Regarding EC-treated animals, the highest dose group exhibited a maximal %MN-PCE value of 1.50 AE 0.22%, an~7.5-fold increase over the vehicle control (Fig. 5B) . Similar to the measurements in peripheral blood, significant decreases in %PCE were noted for both the PCZ and EC treatment groups. Figure 6 shows the results of the Comet analyses using peripheral blood samples on Day 4 of the 3-day study. Statistically significant, dose-dependent increases in median %tail DNA occurred in each dose group of PCZexposed animals, indicating DNA damage to hematopoietic cells. The maximal %tail DNA values were 13.6 AE 0.16% in the 150 mg/kg/day group, an~6.9-fold increase over the vehicle control (Fig. 6A ). In addition, modest increases in median %tail DNA were observed in EC-treated animals, but they were only significant at the highest-dose level for which the %tail DNA value of 3.13 AE 0.18% (an~1.6-fold increase over the control) was observed (Fig. 6B) . Statistically significantly differences (*) from the same-day vehicle control values were established at P < 0.05 using a one-sided Dunnett's t-test. . Statistically significantly differences (*) from the same-day vehicle control values were established at P < 0.05 using a one-sided Dunnett's t-test.
Peripheral Blood Comet Assay
28-DAY STUDY
Survival and Clinical Observations
All animals in the 28-day study survived to treatment or recovery termination (Fig. 1) and none exhibited overt signs of toxicity due to PCZ or EC treatment.
Body Weight and Food Consumption
Group mean body weights of rats were significantly affected by treatment with PCZ or EC in a dose-related manner ( Supporting Information, Fig. 1A ). For PCZ-treated animals, group mean body weights were significantly below the vehicle control values throughout the whole study. Additionally, mean body weights for the EC groups were significantly lower than the vehicle control beginning on Day 15 for the low-dose level and Day 12 for the highdose level. However, these statistical significances were not observed in EC-treated rats during the recovery period.
In addition, group mean daily food consumption markedly decreased due to treatment with PCZ or EC and then gradually returned to normal levels over the course of recovery ( Supporting Information, Fig. 1B) , consistent with the mean body weight changes for each group.
Organ Weights
The results obtained for organ weights are summarized in Supporting Information, Table II . A statistically significant difference in organ weight relative to vehicle control at treatment termination was observed as follows: decreased absolute and relative weights of thymus, spleen, and testis and decreased absolute epididymis weight at doses ≥30 mg/kg/day for PCZ-treated animals; decreased absolute weight of lung, liver, and kidney only in the highdose (60 mg/kg/day) PCZ group, along with significantly increased relative weights of these organs due to lower terminal body weights compared with the control. Additionally, significantly decreased absolute and relative weights of spleen were noted at each level in the EC groups and significantly increased relative liver weight only in the highest dose EC group.
At recovery termination, significantly decreased absolute and relative weights of testis and epididymis were found at each dose level in the PCZ groups (Supporting Information, Table III ), indicating that PCZ has a sustained impact on the reproductive system of treated animals. No significant differences in other organ weights relative to control were observed among any of the groups at recovery termination (Supporting Information, Table III ).
Hematology and Clinical Chemistry
The results of the hematology examination at treatment termination are presented in Supporting Information, Table IV . Statistically significant, dose-dependent changes in the analyzed hematology parameters on Day 29 included the following: decreased WBC, NEUT, LYMPH, % LYMPH, MONO, EOS, and BASO, and increased % NEUT at doses ≥30 mg/kg/day for PCZ-treated animals; increased %MONO and decreased RBC and HGB only in the high-dose (60 mg/kg/day) PCZ group. In contrast, significantly decreased WBC and LYMPH and increased HGB were observed in the high-dose EC-treated animals on Day 29, while significantly increased RBC were noted for each dose in the EC groups. At the end of recovery, Statistically significantly differences (*) from the vehicle control were established at P < 0.05 using a two-sided Dunnett's t-test.
most of the hematology indicators returned to normal levels or did not attain statistical differences relative to the control, except for occasional individual differences among the animals (Supporting Information, Table V) .
The clinical chemistry measurements at treatment termination are shown in Supporting Information, Table VI . The parameters that were significantly affected by PCZ on Day 29 were decreased ALP and TP, and increased GLU, TG, and A/G for each dose level; decreased AST, CK, and LDH, as well as increased TBIL and BUN in the high-dose group. In contrast, significant changes in clinical chemistry parameters in EC-treated rats on Day 29 were decreased TBIL and increased TG for each dose level. At recovery termination, most of parameters in the PCZ or EC groups returned to normal levels or did not attain statistical differences relative to the control, except for occasional measurements that maintained significance due to individual differences among the animals (Supporting Information, Table VII ).
Pig-a Assay
As shown in Figure 2D , the PCZ treatment groups exhibited reductions in mean %RET values at early time point(s), but these differences were only significant in lowdose animals on Day 15. A rebound effect was observed at each dose level, with markedly elevated values evident on Day 43.
Treatment with PCZ for 28 consecutive days resulted in significant increases in RET CD59− frequencies at each dose level on Days 15-57 (Fig. 2E) . The peak value occurred on Day 43, when the highest dose group expressed a mean RET CD59-frequency of 323.9 AE 65.8 × 10 −6 , demonstrating an~124.6-fold increase over the vehicle control. After peaking, the RET CD59− frequency slightly declined with additional time. As expected, PCZ-induced RBC CD59− frequencies increased more slowly than RET CD59− . The highdose group showed a maximal mean RBC CD59− value of 262.1 AE 21.1 × 10 −6 on Day 43 (Fig. 2F ). In contrast, the %RET data for EC-exposed animals showed slight responses in bone marrow that did not attain statistical significance for any dose level throughout the Pig-a analyses (Fig. 3D) . However, blood micronucleus measurements revealed that the %RET values were significantly reduced by EC treatments in a dose-related manner on Day 4 (Fig. 4B) .
With protracted EC administration, the mean RET CD59− frequencies markedly increased in a dose-dependent manner, demonstrating maximal expression in the high-dose group on Day 28 (Fig. 3E) . The highest value of 35.3 AE 5.4 × 10 −6 indicated an~7.4-fold increase over the vehicle control. As shown in Figure 3F , RBC CD59− frequencies were modestly elevated in EC-treated rats over several time points, with significant increases evident for each exposure level. Peak or near peak values occurred on Day 43, with little change at the last time point. The greatest mean value of 18.6 AE 2.1 × 10 −6 was detected in the high-dose group on Day 57.
Peripheral Blood MN-RETAssay
There were statistically significant, dose-related increases in mean MN-RET frequencies in the PCZ groups on Days 4 and 29 (Fig. 4A) . The maximal mean value of 4.67 AE 0.77% was expressed at a PCZ dose of 60 mg/kg/ day on Day 29. In contrast, EC markedly increased %MN-RET in a dose-dependent manner on Day 4, while having a modest but statistically significant increase for the two doses on Day 29 (Fig. 4B) . The greatest value of 0.72 AE 0.07% was observed in the highest dose EC group on Day 4.
Furthermore, these increases in %MN-RET for the PCZand EC-treated groups were accompanied by significant decreases in %RET, which is in agreement with the rebound effect in %RET measured in conjunction with Piga analyses.
Bone Marrow MN-PCE Assay
Similar to the %MN-RET endpoint, the micronucleus test in bone marrow showed that %MN-PCE were significantly affected by PCZ or EC treatment for 28 consecutive days. The PCZ-induced MN-PCE frequencies were elevated in a dose-related manner, with the top mean value of 3.64 AE 0.42% observed in the high-dose group upon terminal sacrifice (Fig. 5A) .
For the EC treatment groups, %MN-PCE also showed statistically significant, dose-dependent increases, with the greatest frequencies observed on Day 29: 1.93 AE 0.17% for the high-dose level (Fig. 5B) .
Comet Assay
In addition to the Pig-a and micronucleus endpoints, the Comet assay was conducted using blood and tissue samples-including liver, kidney, and lung-for the 28-day study. As shown in Figures 6A and 7A , statistically significant, dose-dependent increases in median %tail DNA were observed in peripheral blood in the PCZ groups on Days 4 and 29, as well as in all analyzed tissues upon terminal sacrifice.
Similarly, EC also induced modest but significant increases in median %tail DNA in blood samples and all analyzed tissues at each dose level on the day of sacrifice, but no statistically significant effects were observed in peripheral blood on Day 4 (Figs. 6B and 7B ).
DISCUSSION AND SUMMARY
In vivo genotoxicity assays can identify genotoxic carcinogens that are not detected or are difficult to detect Environmental and Molecular Mutagenesis. DOI 10.1002/em in vitro, but that cause measurable genotoxic damage in the tissues of intact animals due to factors such as absorption, distribution, metabolism, and excretion. That is one of the reasons why in vivo assays are an essential part of the standard battery of pharmaceutical safety evaluation tests. Recent revisions of the ICH guidelines (ICH, 2011) allow for the integration of one or more in vivo genotoxicity endpoint(s) into standard toxicology studies, which benefits the reduction of animal usage and provides comprehensive comparative analyses. In this study, we evaluated the integration of several genotoxicity endpoints-including Pig-a, micronucleus, and Comet-into standard acute and subchronic treatment protocols. As would be done in a typical toxicology study, we also measured body and organ weights, food consumption, hematology, and clinical chemistry in the 28-day study. Importantly, we compared relative sensitivities of the different genotoxicity endpoints in the context of the two dosing regimens, and consequently analyzed the merits and demerits of a newly developed gene mutation assay-the Pig-a assay-relative to other, more established endpoints. The test chemicals-PCZ and EC-are well documented to produce negative responses using in vitro genotoxicity tests. Thus, these two compounds are very suitable for evaluating the ability of newly developed in vivo genotoxicity assays to overcome "falsenegative" in vitro results induced by in-vivo-only mutagens.
Procarbazine Hydrochloride
PCZ is a nonclassical oral alkylating anticancer agent that has been used in the treatment of many cancers, including Hodgkin's lymphoma and gliomas (Armand et al., 2007) . PCZ is metabolically activated to form reactive intermediates, presumably the methyl diazonium ion, which reacts with DNA through an S N 1-type mechanism, resulting in relatively large amounts of the mutagenic O 6 -methylguanine (O 6 -meG) (Souliotis et al., 1994; Pletsa et al., 1997) . Based on this mode of action, the mutagenicity of PCZ has been reliably detectable in many in vivo tests, but it has been negative using in vitro genotoxicity assays due to the complex metabolism of the drug and deficiencies in the metabolic activation systems used for in vitro testing (Bronzetti et al., 1979; Suter, 1987; Myhr, 1991; Suzuki et al., 1999) . In our previous in vivo Pig-a study (Pu et al., 2016) , PCZ produced weak positive results in limited testing, where we detected a maximal~2.9-fold increase in mutant erythrocytes. In this study, the leading phenotypic indicator of the Pig-a mutation, the mean RET CD59− frequency, exhibited maximal~75.6-fold and 124.6-fold increases higher than the controls in PCZtreated rats in the 3-day and 28-day studies, respectively. Likewise, the maximal increases in mean RBC CD59− frequencies were~105.9-fold and~374.4-fold over background in the 3-day and 28-day studies, respectively. The strong Pig-a responses described herein for PCZ in the 3-day study are greater than earlier positive Pig-a findings for similar treatments in CD-1 mice treated orally with 37.5-150 mg/kg/day PCZ (Phonethepswath et al., 2013) and in Sprague-Dawley rats exposed intraperitoneally to 100 mg/kg/day PCZ (Revollo et al., 2017) .
In addition to mutagenicity, our experiment showed that PCZ also caused significant clastogenic and DNA damage responses in Sprague-Dawley rats, in both short-term and subchronic treatment protocols. As also is revealed in a number of earlier published studies (almost all conducted in mice) (Wild, 1978; Inouye et al., 1989; Romagna and Schneider, 1990; Vanparys et al., 1990 ; Suzuki et al., represent the standard error of the mean (SEM). Statistically significantly differences (*) from the vehicle control were established at P < 0.05 using a two-sided Dunnett's t-test.
Environmental and Molecular Mutagenesis. DOI 10.1002/em 1999; Phonethepswath et al., 2013) , we found a robust induction of micronuclei in both peripheral blood and bone marrow at all analyzed timepoints or upon terminal sacrifice using both treatment regimens. Similarly, the alkaline Comet assay detected significant %tail DNA increases in the liver, kidney, lung, and peripheral blood of PCZ-treated rats, which is consistent with previous positive findings for these tissue types in PCZ-treated rodents (Sasaki et al., 1998; 2000; Sekihashi et al., 2001) . The positive Comet responses in these tissues/systems are not surprising because these sites are also targets for other relevant genotoxic or carcinogenic effects. For example, the lung and hematopoietic system are the principal targets for PCZ carcinogenesis in mice (IARC, 1981) , and positive results have been observed in liver and kidney in transgenic rodent mutation assays (Suzuki et al., 1999) .
Ethyl Carbamate
The other compound that was tested in this study, EC (also known as urethane), is a versatile carcinogen capable of causing tumors in various tissues and rodent species (Zimmerli and Schlatter, 1991; Benson and Beland, 1997) . Medicinally, EC was once used as an active ingredient in drugs prescribed for the treatment of neoplastic diseases, and as a hypnotic and a mild sedative (Sotomayor and Collins, 1990 ). Similar to PCZ, the available publications show that EC is genotoxic in a variety of in vivo systems, but generally negative in in vitro genotoxicity tests because of its unique metabolism requirements (Sotomayor and Collins, 1990; Forkert and Lee, 1997; Tweats et al., 2007) . The metabolic activation of EC requires CYP2E1 and carboxylesterase isozyme hydrolase A and involves Chydroxylation to form vinyl carbamate, which is then converted to an epoxide that can interact with nucleic acids (Guengerich and Kim, 1991; Forkert and Lee, 1997) .
In our study, the in vivo genotoxicity of EC was readily apparent. The results presented herein indicated that EC induced mutations, clastogenic responses, and DNA damage in both short-term and subchronic treatment designs, but compared with PCZ, the genotoxic effects of EC were relatively weak under some conditions. It is noteworthy that EC caused a significant induction of Pig-a mutant cells: increased RET CD59− and RBC CD59− frequencies were noted in both the 3-day and 28-day studies. The kinetics and magnitude of the mutant cell responses in the 3-day and 28-day studies were very similar to those shown in an experiment conducted by Labash et al. (2015) in male and female rodents exposed to 600 mg/kg/day EC for 3 consecutive days and the research of Bemis et al. (2015) in rats dosed orally for 28 consecutive days with 250 mg/kg/day EC. However, the maximal mutation frequency of RET in our 28-day treatment study with EC (150-300 mg/kg/day), an~13.2-fold increase over the control, was lower than thẽ 74.0-fold increase in a similar study conducted by , where SD rats were treated orally with 25-250 mg/kg/day using the same dosing protocol; while the maximal~26.4-fold increase over the control for mutant RBC in our study is greater than the~8.1-fold increase in the study of . With regards to the micronucleus tests using peripheral blood and bone marrow, EC induced statistically significant, dose-dependent increases in the frequencies of MN-RET and MN-PCE in both acute and repeated dose study designs. Similar positive findings were reported for a 28-day treatment schedule with EC by , who found significant responses for MN-RET at doses ≥100 mg/kg/day, but only at 250 mg/kg/day for the MN-PCE endpoint. This difference in sensitivity between MN-RET and MN-PCE endpoints was attributed to the improved power afforded by scoring many more cells using the automated flow cytometric method in the MN-RET assay. Moreover, positive results for EC have been reported in numerous in vivo micronucleus tests conducted in peripheral blood and/or bone marrow from different rodent species (Wild, 1978; Westmoreland et al., 1991; Williams et al., 1998; Hamada et al., 2001; Tweats et al., 2007) .
Finally, modest but statistically significant increases in %tail DNA were found in peripheral blood at doses ≥150 mg/kg/day on Day 29 in the 28-day study, but no evident increases were observed at any concentration on Day 4. Similarly, there were weak positive Comet results in peripheral blood on Day 4 in the 3-day study, but only at the high dose level (800 mg EC/kg/day). Such discrepant Comet responses in peripheral blood lymphocytes also have been reported in the 28-day study performed by in the same rodent species. Additionally, the modest but statistically significant increases in DNA damage in liver, kidney, and lung upon terminal sacrifice in the 28-day study were slightly different from previous findings reported by , who found positive Comet results only in liver in the highest dose group, but not in brain, kidney, or lung in any group. Also, the positive response in liver reported herein is consistent with the published review by Sasaki et al. (2000) .
Integrated InVivo Genotoxicity Endpoints
Although the two test chemicals in our study, PCZ and EC, have been investigated previously in similar integrated studies as well as assays measuring single genotoxicity endpoints, including Pig-a gene mutation (Phonethepswath et al., 2013; Bemis et al., 2015; Labash et al., 2015; Pu et al., 2016; Revollo et al., 2017) , the data reported herein allow comparisons between the responses for multiple genotoxicity endpoints as a function of two commonly employed treatment regimens (shortterm, 3-day and subchronic, 28-day studies). In addition to conducting multiple genotoxicity assays, analyses were Environmental and Molecular Mutagenesis. DOI 10.1002/em made to collect data for hematology, clinical chemistry, organ weight, and other general toxicity indicators. Thus, we demonstrated the feasibility and efficiency of the integration of gene mutation, chromosome breakage, and DNA damage endpoints into ongoing standard toxicology studies in compliance with Good Laboratory Practice regulations. Indeed, the combination can provide a comprehensive analysis of complementary genotoxicity profiles in concurrent pharmacokinetic and/or routine toxicology studies without the need for dedicated single-endpoint genotoxicity experiments. This has the potential for considerably reducing the number of animals used and saving time and costs associated with the safety evaluations of chemicals.
Importantly, our data show how best to integrate multiple genotoxicity endpoints into a single study. As summarized in Table III , the maximal increases relative to the control for micronucleus and Comet assays generally are greater in the 3-day study than in the 28-day study, while the Pig-a profiles show the opposite. The maximal increases in mutant RET and RBC for both PCZ and EC are greater with the repeated, subchronic dosing protocol than with the acute, short-term treatment regimen. Thus, these results indicate that the micronucleus (in bone marrow and peripheral blood) and Comet endpoints might be more sensitive to positive responses produced by the higher-dose, acute treatments, while the Pig-a assay responds better to the cumulative effects of the lower-dose, but repeated dosing in a subchronic study (e.g., 28-day treatment protocol). An explanation for this may be that the micronucleus and Comet endpoints respond to DNA damage present in a relatively narrow window of time (hours to days) and thus produce greater responses with shorter, but higher dose in acute treatment regimens. The peripheral blood/bone marrow micronucleus test assesses cytogenetic damage to erythroblasts in bone marrow, which generally move into blood from 24 to 48 hr; the Comet assay detects primary DNA damage including short-term repairable damage that can only be measured from 3-6 hours after treatment. The lower doses tolerated in repeated subchronic treatment studies result in lower levels of DNA damage or chromosome alterations in the narrow time window sampled by the micronucleus or Comet assay. In contrast, gene mutations that require a lengthy expression time relative to the other genotoxicity endpoints can accumulate in vivo as a consequence of repeated exposure of mutagen, and therefore benefit from the higher total doses achieved by repeated subchronic/chronic treatments (Hitotsumachi et al., 1985; Aidoo et al., 1993) .
In addition, the Pig-a data in this study confirmed a good performance of the newly developed gene mutation assay using two commonly employed experimental schedules. As observed in previous studies for other genotoxic compounds Phonethepswath et al., 2010; Dertinger et al., 2012) , PCZ and EC showed a similar response characterized by the accumulation of Pig-a mutations in red blood cells with repeated dosing and persistence for considerable periods of time after short-term acute exposure. These observations suggest that the underlying Pig-a mutation is a neutral or nearly neutral event occurring in hematopoietic progenitor cells. Moreover, as reported by Dertinger et al. (2011a) , the immunomagnetic separation procedure used in this study can dramatically increase the rates of acquiring Pig-a data and therefore facilitates rapid analyses (<6 min per sample) and improves the statistical power of the assay. Notably, the high statistical power can enhance the precision of mutation measurements, which is especially important for weak or presumably nongenotoxic agents. In this case of EC, its weak positive results were more evident in the Pig-a assay compared with the micronucleus or Comet endpoint, regardless of the dosing schedule. In contrast, the magnitude of MN-RET/MN-PCE and Comet responses was similar for each dose on both sampling days in the 28-day study, reflecting no accumulation of these endpoints as a consequence of repeated daily exposure to PCZ or EC.
Comparing the different genotoxicity endpoints also indicates how the various genotoxic assays tend to complement each other from a practical standpoint. For example, as discussed above, the assessment of RBC CD59− and RET CD59− may be a more useful and sensitive genotoxicity endpoint to evaluate lower doses of weak mutagens in subchronic/chronic dosing protocols. Nevertheless, a major problem with the Pig-a assay is that it only measures mutations induced in bone marrow; also, the target tissue for micronucleus test is usually the hematopoietic system, although methods have been established to assess micronuclei in other tissues such as liver (Igarashi and Shimada, 1997; Takasawa et al., 2013) . These blood or bone marrow endpoints may be complementary with the Comet assay because it can detect DNA damage in a wide variety of tissues as long as a single cell suspension can be obtained. What is more, an analysis of the published literature indicated that the bone marrow micronucleus test has a sensitivity of <50% for detecting known rodent carcinogens, while almost 90% of the micronucleus-negative or equivocal carcinogens produced positive responses in the Comet assay (Kirkland and Speit, 2008) . Under these circumstances, the Comet assay has been recommended in ICH S2 (R1) guidelines (ICH, 2011) as an appropriate complement to the micronucleus test.
Collectively, these results support the view that the integration of several in vivo genotoxicity endpoints into a single routine toxicology study is feasible and has the benefit of providing valuable insights into the modes of action of genotoxic test agents. We also conclude that the Pig-a assay may be more suitable for integration in repeated dosing protocols, especially in the case of lower doses of relatively weak genotoxicants, due to its characteristics of accumulation and persistence of mutation, whereas the micronucleus and Comet endpoints can respond with more Environmental and Molecular Mutagenesis. DOI 10.1002/em sensitivity in the cases of higher dose, acute treatment regimens. Nevertheless, some weak or negative responses for EC at certain analyzed timepoints and/or at lower doses demonstrate that not all genotoxicity endpoints show a similar sensitivity at the same dose level. Thus, concerns should be focused on the selection of treatment protocols, doses, endpoints, and tissues when incorporating multiple assays to assess genotoxic potentials in one set of animals. Also, bioavailability, metabolism, and the genotoxic modes of action of the test compound must be taken into account in designing an integrated multiple-endpoint study.
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